Lorlatinib Salvages CNS Relapse in an ALK-Positive Non–Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib - Clinical Lung Cancer
Assessment report
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study | SpringerLink
A user's guide to lorlatinib - ScienceDirect
Lorlatinib - LiverTox - NCBI Bookshelf
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease - Journal of Thoracic Oncology
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer | Nature Communications
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer | Nature Communications
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study | SpringerLink
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer | Nature Cancer
Lorviqua 25 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc)
a Plasma lorlatinib and b metabolite (M8) concentration-time profiles... | Download Scientific Diagram
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM
Practical management of major Lorlatinib side effects — ALK POSITIVE
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial - The Lancet Oncology
Summary of Plasma Lorlatinib Pharmacokinetic Parameters Following a... | Download Scientific Diagram
A user's guide to lorlatinib - ScienceDirect
Lorlatinib (Pfizer Inc) | Bioz | Ratings For Life-Science Research
Lorlatinib | C21H19FN6O2 - PubChem
Lorlatinib - Wikipedia
Median plasma lorlatinib concentration–time profiles following... | Download Scientific Diagram
Pharmaceuticals | Free Full-Text | Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis | HTML
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse | JCO Precision Oncology
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants | SpringerLink
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study | SpringerLink
Lorlatinib Approved for ALK-Positive NSCLC | LCFA
